Monoclonal antibodies (mAbs) have been developed to improve the treatment outcome of cancer patients undergoing therapy according to multimodality regimens without a significant increase of treatment-associated toxicity. This five-chapter book provides examples where mAbs that have become part of the standard of care in cancer patients and cancer types that have responded to mAbs. Individual chapters devoted to each target cancer type illustrate the importance of recognizing and leveraging the unique features of the respective mAb in order to fully realize their therapeutic potential.
